ADC Therapeutics' IFRS loss for 3 months of 2022 was $16.661 million, down 3.1 times from $51.527 million in the previous year. Revenues were $46.498 million. The company did not generate revenues a year earlier.
ADC Therapeutics' IFRS loss for 3 months of 2022 was $16.661 million, down 3.1 times from $51.527 million in the previous year. Revenues were $46.498 million. The company did not generate revenues a year earlier. 
ir.adctherapeutics.com
English (US) 